IP Library › Granted Patent US 11,279,760
Granted Patent B2
US 11,279,760 · App. 17/379,128 · Granted Mar 22, 2022

Inhibition of cytokine-induced SH2 protein in NK cells

Inventors: Nicholas D. Huntington (Parkville, AU); Sandra E. Nicholson (Parkville, AU)
Assignee: The Walter and Eliza Hall Institute of Medical Research
C07K16/2818A61K31/506A61K31/713A61K35/17A61K38/04A61K38/1709A61K39/395A61P35/00A61P35/02C07K16/18C07K16/22C07K16/2803C12N5/0646G01N33/566G01N33/6863A61K2039/505A61K2039/507
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,279,760
App. No.
17/379,128
Granted
Mar 22, 2022
Kind
B2
Abstract

The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.

Claims (13)

1. CIS-inhibited human NK cells, wherein the CIS-inhibited human NK cells are genetically modified to have reduced expression of CIS, or are genetically modified to express a dominant negative CIS sequence variant or dominant negative fragment thereof.

2. The CIS-inhibited human NK cells of claim 1 , wherein the CIS-inhibited human NK cells are NK cells genetically modified to have reduced expression of CIS.

3. The CIS-inhibited human NK cells of claim 1 , wherein the CIS-inhibited human NK cells are Cish −/− .

4. The CIS-inhibited human NK cells of claim 1 , in which the Cish gene has been genetically deleted.

5. The CIS-inhibited human NK cells of claim 1 , wherein expression of CIS protein has been reduced by a gene silencing strategy.

6. The CIS-inhibited human NK cells of claim 5 , wherein the gene silencing strategy comprises use of siRNA or RNAi.

7. The CIS-inhibited human NK cells of claim 1 , wherein the CIS-inhibited human NK cells are genetically modified to express a dominant negative CIS sequence variant or dominant negative fragment thereof.

8. The CIS-inhibited human NK cells of claim 1 , wherein the CIS-inhibited human NK cells are irreversibly genetically modified.

9. The CIS-inhibited human NK cells of claim 1 , wherein the CIS-inhibited human NK cells are reversibly genetically modified so that over time the CIS inhibition in the NK cells decreases.

10. Human Cish −/+ NK cells.

11. Human Cish −/− NK cells.

12. A composition comprising the human Cish −/− NK cells of claim 11 .

13. A pharmaceutical composition comprising the human Cish −/− NK cells of claim 11 .

Priority Claims (1)
AU 2015905220 · Dec 16, 2015 · national
Continuity (3)
Continuation 17115896 · Dec 9, 2020
Division 16060996
Related Publication 20220025048A1 · Jan 27, 2022